PROCEPT BioRobotics Corp(PRCT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

PROCEPT BioRobotics Corp (PRCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRCT at 33.3/100 on a 32-signal composite quality model, placing it at rank #2,395 of 2,960 stocks — the bottom half of the AI-ranked universe. PRCT scores in the top quartile across revenue growth (92.1). Areas of concern include balance sheet strength (10.3) and free cash flow (12.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PROCEPT BioRobotics Corp reports quarterly revenue of $94.5M, net income of $-26.9M, an operating margin of -29.0%. Top institutional holders of PRCT by reported 13-F value include BlackRock, T. Rowe Price Investment Management, BNP Paribas Asset Management Holding S.A., based on the most recent SEC filings. PRCT trades on the Nasdaq exchange and files with the SEC under CIK 1588978. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PROCEPT BioRobotics Corp directly from SEC EDGAR.